Segantii Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History
Bought
Maintained
Sold
Other funds holding TRIL
Segantii Capital Management's TRIL Position: Q4 2021 in Review
Segantii Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 1,135,000 shares — an estimated $19.9M sold.
Segantii Capital Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $19.9M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.
- Segantii Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
- Segantii Capital Management sold 1,135,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $19.9M.
- Segantii Capital Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
- Segantii Capital Management's Trillium Therapeutics Inc. position peaked at $19.9M in Q3 2021.
- 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.
Based on Segantii Capital Management's 13F filing for Q4 2021, filed 21 Jan 2022.